Amna A Ghouse1, Marsal Sanches1, Giovana B Zunta-Soares1, Jair C Soares2. 1. UT Center of Excellence on Mood Disorders, Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston, Houston, TX, USA. 2. UT Center of Excellence on Mood Disorders, Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston, Houston, TX, USA. Electronic address: jair.c.soares@uth.tmc.edu.
Abstract
BACKGROUND: The "spectrum" model has advantages for the conceptualization of mental disorders, representing a complementary approach to the currently available categorical systems. We carried out a study in order to assess lifetime mood symptoms among patients with bipolar disorder (BD) and healthy controls from a dimensional perspective. METHODS: The Mood Spectrum Self-Report instrument (MOODS-SR) was administered to 101 bipolar patients (52 BD I, 32 BD II, and 17 BD NOS, 36 males/65 females, mean age+SD=36.10±13.34 years) and 38 healthy controls (16 males/22females, mean age+SD=35.18±13.70 years). The scores of the different MOOD-SR scales and subscales among patients and controls were compared using non-parametric tests (Mann-Whitney and Kruskal-Wallis). RESULTS: Bipolar patients scored significantly higher than healthy controls on the total MOOD-SR scores (BD: mean±SD=98.65±22.17; HC: mean±SD=12.92±10.72; p<0.01) and all subdomains. Multiple comparisons revealed lower scores among controls when compared to each one of the subtypes of BD, also regarding the total scores and all subdomains (p<0.01). Comparisons across the different subtypes of BD revealed statistically significant higher scores among BD I patients when compared to BD II and BD NOS patients, only in regard to the total MOOD-SR scores (BD I: mean±SD=102.94±22.79; BD II: mean±SD=93.53±21.97; BD NOS: mean±SD= 94.88±18.68; p=0.03) and two subdomains: mood mania and energy mania. CONCLUSIONS: These results, although preliminary, suggest that even though the MOODS-SR seems effective in distinguishing BD patients from HC, it is not as good in discriminating different subtypes of BD, especially in respect to lifetime depressive symptoms. LIMITATIONS: Our sample size was small, and comprised by outpatients. The MOOD-SR measures only lifetime symptoms and does not take into account the progression of mood symptoms or the current mood state of patients.
BACKGROUND: The "spectrum" model has advantages for the conceptualization of mental disorders, representing a complementary approach to the currently available categorical systems. We carried out a study in order to assess lifetime mood symptoms among patients with bipolar disorder (BD) and healthy controls from a dimensional perspective. METHODS: The Mood Spectrum Self-Report instrument (MOODS-SR) was administered to 101 bipolarpatients (52 BD I, 32 BD II, and 17 BD NOS, 36 males/65 females, mean age+SD=36.10±13.34 years) and 38 healthy controls (16 males/22females, mean age+SD=35.18±13.70 years). The scores of the different MOOD-SR scales and subscales among patients and controls were compared using non-parametric tests (Mann-Whitney and Kruskal-Wallis). RESULTS:Bipolarpatients scored significantly higher than healthy controls on the total MOOD-SR scores (BD: mean±SD=98.65±22.17; HC: mean±SD=12.92±10.72; p<0.01) and all subdomains. Multiple comparisons revealed lower scores among controls when compared to each one of the subtypes of BD, also regarding the total scores and all subdomains (p<0.01). Comparisons across the different subtypes of BD revealed statistically significant higher scores among BD I patients when compared to BD II and BD NOS patients, only in regard to the total MOOD-SR scores (BD I: mean±SD=102.94±22.79; BD II: mean±SD=93.53±21.97; BD NOS: mean±SD= 94.88±18.68; p=0.03) and two subdomains: mood mania and energy mania. CONCLUSIONS: These results, although preliminary, suggest that even though the MOODS-SR seems effective in distinguishing BD patients from HC, it is not as good in discriminating different subtypes of BD, especially in respect to lifetime depressive symptoms. LIMITATIONS: Our sample size was small, and comprised by outpatients. The MOOD-SR measures only lifetime symptoms and does not take into account the progression of mood symptoms or the current mood state of patients.
Authors: Giovanni B Cassano; Ellen Frank; Mario Miniati; Paola Rucci; Andrea Fagiolini; Stefano Pini; M Katherine Shear; Jack D Maser Journal: Psychiatr Clin North Am Date: 2002-12
Authors: Lewis L Judd; Hagop S Akiskal; Pamela J Schettler; Jean Endicott; Andrew C Leon; David A Solomon; William Coryell; Jack D Maser; Martin B Keller Journal: Arch Gen Psychiatry Date: 2005-12
Authors: Jules Angst; Rolf Adolfsson; Franco Benazzi; Alex Gamma; Elie Hantouche; Thomas D Meyer; Peter Skeppar; Eduard Vieta; Jan Scott Journal: J Affect Disord Date: 2005-10 Impact factor: 4.839
Authors: G B Cassano; L Dell'Osso; E Frank; M Miniati; A Fagiolini; K Shear; S Pini; J Maser Journal: J Affect Disord Date: 1999-08 Impact factor: 4.839
Authors: S Nassir Ghaemi; Christopher J Miller; Douglas A Berv; Jeffry Klugman; Klara J Rosenquist; Ronald W Pies Journal: J Affect Disord Date: 2005-02 Impact factor: 4.839
Authors: Leticia de Oliveira; Liana C L Portugal; Mirtes Pereira; Henry W Chase; Michele Bertocci; Richelle Stiffler; Tsafrir Greenberg; Genna Bebko; Jeanette Lockovich; Haris Aslam; Janaina Mourao-Miranda; Mary L Phillips Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2019-04-17